BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: The maximum plasma levels (~100 nM) and prolonged elimination half-life (>24 h) of Ponatinib in standard of care dose for CML suggest that Ponatinib would be clinically effective for targeting BRAF and ERK signaling inhibition48.